Phase 2 study of montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia

Trial Profile

Phase 2 study of montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 22 Aug 2016 According to an IntelGenx media release, the company expects results from this study to be available in Q4 of 2017.
    • 22 Aug 2016 According to an IntelGenx media release, patient enrolment for this study is expected to commence in Q1 of 2017.
    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top